Back to Search
Start Over
Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTherâ„¢) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
- Source :
- Cancer Biotherapy and Radiopharmaceuticals. 18:581-588
- Publication Year :
- 2003
- Publisher :
- Mary Ann Liebert Inc, 2003.
-
Abstract
- The purpose of this study was to determine whether there is evidence for hepatocellular radiation injury following treatment with (90)Y-SMT487 ((90)Y-DOTA-tyr3-octreotide, OctreoTher(TM)) in patients with extensive liver metastases from neuroendocrine tumors. Patients reported in this study participated in a Phase II trial of efficacy and safety of (90)Y-SMT487. The trial design called for three treatment cycles of 120 mCi each (4400 MBq) of (90)Y-SMT487. (111)In-pentetreotide SPECT images were used to determine the extent of liver metastases. Serum AST, ALT, and alkaline phosphatase levels were obtained at baseline and following each cycle of therapy. Least squares fit was applied to the serial liver enzyme measurements in patients with extensive liver metastases. Post-therapy liver enzyme measurements were also evaluated using WHO common toxicity criteria. Repeated-measures ANOVA and paired t-test were applied to the serial enzyme measures. There were 21 subjects. Fifteen of these had hepatic metastases with 12 demonstrating extensive (defined as 25% or more) liver involvement. In only 4 of these 15 did any of the three enzyme levels increase in WHO toxicity grade from baseline to final follow-up. We conclude that patients with diffuse SSTR positive hepatic metastases can be treated with a cumulative administered activity of 360 mCi (90)Y-SMT487 with only a small chance of developing mild acute or subacute hepatic radiation injury.
- Subjects :
- Cancer Research
medicine.medical_specialty
Pathology
medicine.medical_treatment
Octreotide
Neuroendocrine tumors
Gastroenterology
Metastasis
Clinical Protocols
Internal medicine
medicine
Humans
Yttrium Radioisotopes
Radiology, Nuclear Medicine and imaging
Aspartate Aminotransferases
Receptors, Somatostatin
Tomography, Emission-Computed, Single-Photon
Pharmacology
Analysis of Variance
Chemotherapy
Somatostatin receptor
business.industry
Liver Neoplasms
Alanine Transaminase
General Medicine
Alkaline Phosphatase
medicine.disease
Carcinoma, Neuroendocrine
Liver
Oncology
Toxicity
Disease Progression
Alkaline phosphatase
Radiopharmaceuticals
Somatostatin
business
Chemoradiotherapy
medicine.drug
Subjects
Details
- ISSN :
- 15578852 and 10849785
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Cancer Biotherapy and Radiopharmaceuticals
- Accession number :
- edsair.doi.dedup.....115f5e369e7ac5daa775ece7fdd6bba1